Comparing Two Different Boost Approaches in Radiation Therapy for People With Prostate Cancer

Purpose

In this study we will find out whether the use of a new type of boost approach called irreversible electroporation (IRE) is as effective as the standard boost approach of radiation therapy for people with intermediate-risk prostate cancer receiving standard stereotactic body radiotherapy (SBRT).

Condition

  • Prostate Cancer

Eligibility

Eligible Ages
Between 18 Years and 99 Years
Eligible Sex
Male
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Biopsy proven grade group 2 or 3 (GS 3+4 or GS 4+3) cancer with all pattern 4 found only in the MRI target - Gland size ≤ 80 cc - Prostate MRI < rT3b disease - IPSS < 20 - No contraindication to IRE, RT, anesthesia, or transperineal procedure

Exclusion Criteria

  • Any Grade Group ≥4 disease, or any cribriform and/or intraductal carcinoma - Evidence of nodal or /metastatic disease on MRI and/or PSMA PET/CT - Unfit for general anesthesia, or contraindication/hypersensitivity to required neuromuscular blocking agents - Active urinary tract infection (UTI) at the time of IRE or biopsy; must be treated and resolved prior to proceeding - Actively bleeding, known bleeding disorder, or inability to interrupt anticoagulants/antiplatelet therapy as clinically indicated for biopsy/IRE safety - Any history of cardiac arrhythmia or epilepsy, or recent myocardial infarction, consistent with NanoKnife contraindication statements - Presence of an implanted pacemaker/defibrillator or other active implanted electronic device, or other device-related contraindications per current NanoKnife labeling/user manual - Inability to undergo pelvic MRI - Prior treatment of prostate cancer including androgen deprivation therapy, focal therapy, radiation therapy, or prostatectomy - Current or intended use of androgen deprivation therapy

Study Design

Phase
Phase 3
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
IRE Boost Arm
Participants will receive Irreversible Electroporation
  • Device: NanoKnife System
    The NanoKnife System is the device that is used for Irreversible Electroporation/IRE. The NanoKnife Generator is a microprocessor-controlled low energy direct current (LEDC) irreversible electroporation device.
  • Radiation: Stereotactic Body Radiation Therapy
    Radiation-based treatment intensification involves delivery of a boost to the dominant intraprostatic lesion (DIL) to a higher dose than the surrounding prostate tissue using external beam radiation therapy.
    Other names:
    • SBRT
Active Comparator
RT Boost Arm
Participants will receive Radiation Therapy and will serve as the control arm
  • Radiation: Stereotactic Body Radiation Therapy
    Radiation-based treatment intensification involves delivery of a boost to the dominant intraprostatic lesion (DIL) to a higher dose than the surrounding prostate tissue using external beam radiation therapy.
    Other names:
    • SBRT

Recruiting Locations

Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)
Basking Ridge, New Jersey 07920
Contact:
Himanshu Nagar, MD
212-639-6478

Memorial Sloan Kettering at Monmouth (Limited Protocol Activities)
Middletown, New Jersey 07748
Contact:
Himanshu Nagar, MD
212-639-6478

Memorial Sloan Kettering at Bergen (Limited Protocol Activities)
Montvale, New Jersey 07645
Contact:
Himanshu Nagar, MD
212-639-6478

Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities)
Commack, New York 11725
Contact:
Himanshu Nagar, MD
212-639-6478

Memorial Sloan Kettering at Westchester (Limited Protocol Activities)
Harrison, New York 10604
Contact:
Himanshu Nagar, MD
212-639-6478

Memorial Sloan Kettering Cancer Center (All Protocol Activites)
New York, New York 10065
Contact:
Himanshu Nager, MD
212-639-6478

Memorial Sloan Kettering at Nassau (Limited Protocol Activities)
Uniondale, New York 11553
Contact:
Himanshu Nagar, MD
212-639-6478

More Details

Status
Recruiting
Sponsor
Memorial Sloan Kettering Cancer Center

Study Contact

Himanshu Nagar, MD
212-639-6478
nagarh1@mskcc.org